Inflammatory myopathy associated with PD-1 inhibitors

To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal reco...

Full description

Saved in:
Bibliographic Details
Published inJournal of autoimmunity Vol. 100; pp. 105 - 113
Main Authors Seki, Morinobu, Uruha, Akinori, Ohnuki, Yuko, Kamada, Sachiko, Noda, Tomoko, Onda, Asako, Ohira, Masayuki, Isami, Aiko, Hiramatsu, Sumie, Hibino, Makoto, Nakane, Shunya, Noda, Seiya, Yutani, Sachiko, Hanazono, Akira, Yaguchi, Hiroshi, Takao, Masaki, Shiina, Takashi, Katsuno, Masahisa, Nakahara, Jin, Matsubara, Shiro, Nishino, Ichizo, Suzuki, Shigeaki
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.06.2019
Subjects
Online AccessGet full text
ISSN0896-8411
1095-9157
1095-9157
DOI10.1016/j.jaut.2019.03.005

Cover

Loading…
Abstract To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects. In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness. Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy. •We characterized the inflammatory myopathy associated with PD-1inhibitors.•Ocular, facial, cardiac and respiratory involvement and myalgia were often found.•Anti-striational antibodies were detected in 13 patients (68%).•Pathology showed multifocal necrotic myofibers and expression of MHC class I.•Corticosteroids were effective with the prompt normalization of CK.
AbstractList To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).OBJECTIVETo characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects.METHODSWe studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects.In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness.RESULTSIn regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness.Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy.CONCLUSIONSBased on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy.
To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects. In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness. Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy. •We characterized the inflammatory myopathy associated with PD-1inhibitors.•Ocular, facial, cardiac and respiratory involvement and myalgia were often found.•Anti-striational antibodies were detected in 13 patients (68%).•Pathology showed multifocal necrotic myofibers and expression of MHC class I.•Corticosteroids were effective with the prompt normalization of CK.
To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects. In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness. Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy.
Author Hibino, Makoto
Onda, Asako
Katsuno, Masahisa
Nakahara, Jin
Matsubara, Shiro
Shiina, Takashi
Uruha, Akinori
Ohnuki, Yuko
Nishino, Ichizo
Yutani, Sachiko
Ohira, Masayuki
Suzuki, Shigeaki
Noda, Seiya
Takao, Masaki
Kamada, Sachiko
Nakane, Shunya
Hanazono, Akira
Seki, Morinobu
Yaguchi, Hiroshi
Noda, Tomoko
Isami, Aiko
Hiramatsu, Sumie
Author_xml – sequence: 1
  givenname: Morinobu
  surname: Seki
  fullname: Seki, Morinobu
  organization: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
– sequence: 2
  givenname: Akinori
  surname: Uruha
  fullname: Uruha, Akinori
  organization: Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo, 183-0042, Japan
– sequence: 3
  givenname: Yuko
  surname: Ohnuki
  fullname: Ohnuki, Yuko
  organization: Department of Medical Ethics, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan
– sequence: 4
  givenname: Sachiko
  surname: Kamada
  fullname: Kamada, Sachiko
  organization: Department of Neurology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
– sequence: 5
  givenname: Tomoko
  surname: Noda
  fullname: Noda, Tomoko
  organization: Department of Neurology, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya-shi, Aichi, 491-8558, Japan
– sequence: 6
  givenname: Asako
  surname: Onda
  fullname: Onda, Asako
  organization: Department of Neurology, Jikei University Kashiwa Hospital, 163-1 Kashiwashita Kashiwa-shi, Chiba, 277-8567, Japan
– sequence: 7
  givenname: Masayuki
  surname: Ohira
  fullname: Ohira, Masayuki
  organization: Department of Neurology, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan
– sequence: 8
  givenname: Aiko
  surname: Isami
  fullname: Isami, Aiko
  organization: Department of Neurology, Nagaoka Red Cross Hospital, 2-297-1, Sensyu, Nagaoka-shi, Niigata, 940-2085, Japan
– sequence: 9
  givenname: Sumie
  surname: Hiramatsu
  fullname: Hiramatsu, Sumie
  organization: Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-0914, Japan
– sequence: 10
  givenname: Makoto
  surname: Hibino
  fullname: Hibino, Makoto
  organization: Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, 1-5-1 Tsujido Kandai, Fujisawa-shi, Kanagawa, 251-0041, Japan
– sequence: 11
  givenname: Shunya
  surname: Nakane
  fullname: Nakane, Shunya
  organization: Department of Molecular Neurology and Therapeutics, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan
– sequence: 12
  givenname: Seiya
  surname: Noda
  fullname: Noda, Seiya
  organization: Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466–8550, Japan
– sequence: 13
  givenname: Sachiko
  surname: Yutani
  fullname: Yutani, Sachiko
  organization: Department of Neurology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan
– sequence: 14
  givenname: Akira
  surname: Hanazono
  fullname: Hanazono, Akira
  organization: Department of Neurology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
– sequence: 15
  givenname: Hiroshi
  surname: Yaguchi
  fullname: Yaguchi, Hiroshi
  organization: Department of Neurology, Jikei University Kashiwa Hospital, 163-1 Kashiwashita Kashiwa-shi, Chiba, 277-8567, Japan
– sequence: 16
  givenname: Masaki
  surname: Takao
  fullname: Takao, Masaki
  organization: Department of Neurology, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan
– sequence: 17
  givenname: Takashi
  surname: Shiina
  fullname: Shiina, Takashi
  organization: Department of Molecular Life Science, Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan
– sequence: 18
  givenname: Masahisa
  surname: Katsuno
  fullname: Katsuno, Masahisa
  organization: Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466–8550, Japan
– sequence: 19
  givenname: Jin
  surname: Nakahara
  fullname: Nakahara, Jin
  organization: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
– sequence: 20
  givenname: Shiro
  surname: Matsubara
  fullname: Matsubara, Shiro
  organization: Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo, 183-0042, Japan
– sequence: 21
  givenname: Ichizo
  surname: Nishino
  fullname: Nishino, Ichizo
  organization: Department of Neuromuscular Research, National Institute of Neuroscience, And Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8502, Japan
– sequence: 22
  givenname: Shigeaki
  surname: Suzuki
  fullname: Suzuki, Shigeaki
  email: sgsuzuki@z3.keio.jp
  organization: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30862448$$D View this record in MEDLINE/PubMed
BookMark eNqFkE9P3DAQRy0EguXPF-ihyrGXpDOJk9hVLxUtFAkJDu3Zsp2J1tsk3tpeqnz7ZrVw4QCnubz3k-ads-PJT8TYB4QCAZvPm2Kjd6koAWUBVQFQH7EVgqxziXV7zFYgZJMLjnjGzmPcACDWdX3KzioQTcm5WLH6buoHPY46-TBn4-y3Oq3nTMfordOJuuyfS-vs8XuOmZvWzrgFjJfspNdDpKvne8F-3_z4df0zv3-4vbv-dp9bDm3Ked2aBnogyateNNqYshcGG8LSaAFc9K0kNIJXZkE7S6WkRvKOW2FIW11dsE-H3W3wf3cUkxpdtDQMeiK_i6pEibA83MKCfnxGd2akTm2DG3WY1curCyAOgA0-xkC9si7p5PyUgnaDQlD7qmqj9lXVvqqCSi1VF7V8pb6svyl9PUi0BHpyFFS0jiZLnQtkk-q8e1v_8kq3g5uc1cMfmt-T_wNBn6Ot
CitedBy_id crossref_primary_10_2147_EB_S277760
crossref_primary_10_3233_JND_200504
crossref_primary_10_1002_ccr3_9153
crossref_primary_10_1093_braincomms_fcaa181
crossref_primary_10_1212_NXI_0000000000000735
crossref_primary_10_1097_RHU_0000000000001874
crossref_primary_10_2169_internalmedicine_1222_22
crossref_primary_10_2169_internalmedicine_4467_20
crossref_primary_10_2169_naika_108_1793
crossref_primary_10_1007_s10072_022_05920_4
crossref_primary_10_1186_s42466_022_00226_4
crossref_primary_10_1007_s00262_021_03053_9
crossref_primary_10_1007_s10072_021_05561_z
crossref_primary_10_1002_mus_26676
crossref_primary_10_5692_clinicalneurol_cn_001876
crossref_primary_10_3389_fonc_2022_1074821
crossref_primary_10_1210_clinem_dgab829
crossref_primary_10_1093_oncolo_oyac033
crossref_primary_10_3389_fcvm_2021_727445
crossref_primary_10_24911_ejmcr_173_1669055719
crossref_primary_10_1002_art_41713
crossref_primary_10_1080_1744666X_2024_2323966
crossref_primary_10_3389_fphar_2022_774170
crossref_primary_10_1212_WNL_0000000000210031
crossref_primary_10_3389_fgene_2023_1206034
crossref_primary_10_3389_fimmu_2023_1163633
crossref_primary_10_17925_USN_2022_18_1_58
crossref_primary_10_1097_WCO_0000000000001188
crossref_primary_10_1097_ICU_0000000000000608
crossref_primary_10_2169_naika_110_1611
crossref_primary_10_1097_WCO_0000000000000855
crossref_primary_10_1097_CAD_0000000000001665
crossref_primary_10_2169_internalmedicine_6834_20
crossref_primary_10_1016_j_nmd_2020_02_013
crossref_primary_10_1038_s41392_022_01136_2
crossref_primary_10_1111_cen3_12643
crossref_primary_10_1007_s40265_021_01507_z
crossref_primary_10_1093_rheumatology_keab249
crossref_primary_10_2957_kanzo_65_327
crossref_primary_10_1155_2020_5126717
crossref_primary_10_3389_fimmu_2021_701951
crossref_primary_10_3389_fneur_2022_1004810
crossref_primary_10_1016_j_neurol_2023_03_003
crossref_primary_10_1093_noajnl_vdab107
crossref_primary_10_2169_internalmedicine_1801_23
crossref_primary_10_1111_ncn3_12563
crossref_primary_10_1002_art_41604
crossref_primary_10_1016_j_mcna_2020_09_009
crossref_primary_10_1080_14740338_2024_2363471
crossref_primary_10_3389_fonc_2022_1053370
crossref_primary_10_3389_fimmu_2021_803410
crossref_primary_10_3389_fmed_2021_762247
crossref_primary_10_1002_emp2_12209
crossref_primary_10_1210_clinem_dgad231
crossref_primary_10_1016_j_rdc_2022_02_002
crossref_primary_10_3390_ijms24065643
crossref_primary_10_3390_ijms21093054
crossref_primary_10_1093_rheumatology_keaa832
crossref_primary_10_1007_s11910_024_01336_z
crossref_primary_10_1016_j_praneu_2020_01_012
crossref_primary_10_1016_j_praneu_2023_01_011
crossref_primary_10_1111_cen3_12611
crossref_primary_10_1200_OP_20_00625
crossref_primary_10_2169_internalmedicine_0739_22
crossref_primary_10_1136_jitc_2021_002890
crossref_primary_10_5692_clinicalneurol_cn_001604
crossref_primary_10_5692_clinicalneurol_cn_001725
crossref_primary_10_1007_s11926_023_01120_x
crossref_primary_10_1038_s41582_024_01001_6
crossref_primary_10_1007_s00011_023_01780_6
crossref_primary_10_1080_1744666X_2023_2154656
crossref_primary_10_1097_CCO_0000000000000681
crossref_primary_10_1111_cen3_12824
crossref_primary_10_1111_jns_12339
crossref_primary_10_1007_s13760_021_01760_9
crossref_primary_10_5692_clinicalneurol_cn_001443
crossref_primary_10_5692_clinicalneurol_cn_001323
crossref_primary_10_2169_naika_111_1926
Cites_doi 10.1016/j.ejca.2016.12.001
10.1212/WNL.0000000000003160
10.1002/j.1460-2075.1992.tb05481.x
10.1093/brain/aww054
10.1016/j.nmd.2017.01.002
10.1093/annonc/mdw126
10.1097/00000421-198212000-00014
10.1016/j.ctrv.2016.02.001
10.1002/acn3.654
10.1002/rcr2.355
10.1001/jamaneurol.2017.0934
10.1200/JCO.2015.66.1389
10.1093/annonc/mdw655
10.1093/annonc/mdx225
10.1016/j.autrev.2017.05.003
10.1016/S1470-2045(16)30571-X
10.1001/archneurol.2009.229
10.1016/j.ejca.2008.10.026
10.1038/nrneurol.2017.144
10.1161/CIRCULATIONAHA.118.035898
10.1111/nan.12380
10.1126/science.aaa8172
10.1001/jamaneurol.2017.1912
10.1016/S0198-8859(01)00298-1
10.1016/j.ejca.2017.05.041
10.1212/WNL.0000000000004359
10.1016/S0140-6736(66)92356-7
10.1111/j.1399-0039.2012.01941.x
10.1016/j.jneuroim.2010.10.023
10.2169/internalmedicine.1956-18
10.1186/s40425-016-0139-8
10.1056/NEJMoa1609214
10.1093/annonc/mdw558
10.1136/jnnp-2016-313166
10.1097/WCO.0000000000000391
10.1212/WNL.0000000000006124
10.1200/JCO.2017.77.6385
10.1001/jamaoncol.2017.2925
10.1016/j.jneuroim.2014.07.006
10.1056/NEJMra1703481
ContentType Journal Article
Copyright 2019 Elsevier Ltd
Copyright © 2019 Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2019 Elsevier Ltd
– notice: Copyright © 2019 Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1016/j.jaut.2019.03.005
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1095-9157
EndPage 113
ExternalDocumentID 30862448
10_1016_j_jaut_2019_03_005
S0896841119300393
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29J
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AAAJQ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFRF
ABJNI
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFGL
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DM4
DU5
EBS
EFBJH
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDU
HMG
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
LG5
LUGTX
LZ5
M29
M41
MO0
N9A
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSH
SSI
SSZ
T5K
WUQ
XPP
Z5R
ZGI
ZMT
ZU3
~G-
AACTN
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
AAYXX
AGRNS
CITATION
NPM
7X8
ID FETCH-LOGICAL-c407t-457b60f0e943f86abb2f8b16e12ba8048f79e1b843b457dce29e694d4c8beaca3
IEDL.DBID .~1
ISSN 0896-8411
1095-9157
IngestDate Mon Jul 21 11:12:46 EDT 2025
Thu Apr 03 07:08:06 EDT 2025
Thu Apr 24 23:06:49 EDT 2025
Tue Jul 01 03:24:09 EDT 2025
Fri Feb 23 02:20:53 EST 2024
Tue Aug 26 18:13:47 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Autoantibodies
Human leucocyte antigen
Creatine kinase
Programmed cell death 1
Inflammatory myopathy
Language English
License Copyright © 2019 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c407t-457b60f0e943f86abb2f8b16e12ba8048f79e1b843b457dce29e694d4c8beaca3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 30862448
PQID 2191009570
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2191009570
pubmed_primary_30862448
crossref_citationtrail_10_1016_j_jaut_2019_03_005
crossref_primary_10_1016_j_jaut_2019_03_005
elsevier_sciencedirect_doi_10_1016_j_jaut_2019_03_005
elsevier_clinicalkey_doi_10_1016_j_jaut_2019_03_005
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2019
2019-06-00
20190601
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: June 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of autoimmunity
PublicationTitleAlternate J Autoimmun
PublicationYear 2019
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Onda, Miyagawa, Takahashi, Mina, Takagi, Nishino (bib19) 2019
Ohnuki, Suzuki, Shiina, Uruha, Watanabe, Suzuki (bib36) 2016; 87
Allenbach, Benveniste, Goebel, Stenzel (bib33) 2017; 43
Sharma, Allison (bib2) 2015; 348
Haddox, Shenoy, Shah, Kao, Jain, Halfdanarson (bib14) 2017; 28
Suzuki, Uruha, Suzuki, Nishino (bib29) 2017; 16
Ishida, Agata, Shibahara, Honjo (bib1) 1992; 11
Takamatsu, Nakane, Suzuki, Kosaka, Fukushima, Kimura (bib32) 2018; 5
Yshii, Hohlfeld, Liblau (bib12) 2017; 13
Johnson, Balko, Compton, Chalkias, Gorham, Xu (bib27) 2016; 375
Touat, Maisonobe, Knauss, Ben Hadj Salem, Hervier, Aure (bib16) 2018; 91
Watanabe, Uruha, Suzuki, Nakahara, Hamanaka, Takayama (bib20) 2016; 87
Suzuki, Utsugisawa, Yoshikawa, Motomura, Matsubara, Yokoyama (bib38) 2009; 66
Brahmer, Lacchetti, Schneider, Atkins, Brassil, Caterino (bib4) 2018; 36
Shiina, Suzuki, Ozaki, Taira, Kikkawa, Shigenari (bib26) 2012; 80
Postow, Sidlow, Hellmann (bib5) 2018; 378
Wick, Hertenstein, Platten (bib8) 2016; 17
Allenbach, Keraen, Bouvier, Jooste, Champtiaux, Hervier (bib30) 2016; 139
Suzuki, Ishikawa, Konoeda, Seki, Fukushima, Takahashi (bib17) 2017; 89
Cao, Hollenbach, Shi, Shi, Chopek, Fernandez-Vina (bib28) 2001; 62
Weber, Hodi, Wolchok, Topalian, Schadendorf, Larkin (bib34) 2017; 35
Hottinger (bib7) 2016; 29
Anquetil, Salem, Lebrun-Vignes, Johnson, Mammen, Stenzel (bib15) 2018; 138
Eisenhauer, Therasse, Bogaerts, Schwartz, Sargent, Ford (bib23) 2009; 45
van der Geld, Strauss (bib25) 1966; 1
Makarious, Horwood, Coward (bib40) 2017; 82
Vallet, Gaillet, Weiss, Vanhaecke, Saheb, Touitou (bib13) 2016; 27
Kao, Liao, Markovic, Klein, Naddaf, Staff (bib10) 2017; 74
Hibino, Maeda, Horiuchi, Fukuda, Kondo (bib18) 2018; 6
Haanen, Carbonnel, Robert, Kerr, Peters, Larkin (bib3) 2017; 28
Oken, Creech, Tormey, Horton, Davis, McFadden (bib22) 1982; 5
Spain, Diem, Larkin (bib6) 2016; 44
Bilen, Subudhi, Gao, Tannir, Tu, Sharma (bib31) 2016; 4
Suzuki, Utsugisawa, Nagane, Satoh, Kuwana, Suzuki (bib37) 2011; 230
Gonzalez, Puwanant, Lu, Marks, Zivkovic (bib39) 2017; 27
Suzuki, Yonekawa, Kuwana, Hayashi, Okazaki, Kawaguchi (bib24) 2014; 274
Noguchi, Uruha, Suzuki, Hamanaka, Ohnuki, Tsugawa (bib21) 2017; 74
Haratani, Hayashi, Chiba, Kudo, Yonesaka, Kato (bib35) 2018; 4
Cuzzubbo, Javeri, Tissier, Roumi, Barlog, Doridam (bib9) 2017; 73
Spain, Walls, Julve, O'Meara, Schmid, Kalaitzaki (bib11) 2017; 28
Bilen (10.1016/j.jaut.2019.03.005_bib31) 2016; 4
Allenbach (10.1016/j.jaut.2019.03.005_bib33) 2017; 43
van der Geld (10.1016/j.jaut.2019.03.005_bib25) 1966; 1
Kao (10.1016/j.jaut.2019.03.005_bib10) 2017; 74
Haanen (10.1016/j.jaut.2019.03.005_bib3) 2017; 28
Hibino (10.1016/j.jaut.2019.03.005_bib18) 2018; 6
Postow (10.1016/j.jaut.2019.03.005_bib5) 2018; 378
Haddox (10.1016/j.jaut.2019.03.005_bib14) 2017; 28
Eisenhauer (10.1016/j.jaut.2019.03.005_bib23) 2009; 45
Gonzalez (10.1016/j.jaut.2019.03.005_bib39) 2017; 27
Hottinger (10.1016/j.jaut.2019.03.005_bib7) 2016; 29
Suzuki (10.1016/j.jaut.2019.03.005_bib29) 2017; 16
Ohnuki (10.1016/j.jaut.2019.03.005_bib36) 2016; 87
Suzuki (10.1016/j.jaut.2019.03.005_bib17) 2017; 89
Suzuki (10.1016/j.jaut.2019.03.005_bib37) 2011; 230
Suzuki (10.1016/j.jaut.2019.03.005_bib24) 2014; 274
Sharma (10.1016/j.jaut.2019.03.005_bib2) 2015; 348
Anquetil (10.1016/j.jaut.2019.03.005_bib15) 2018; 138
Yshii (10.1016/j.jaut.2019.03.005_bib12) 2017; 13
Touat (10.1016/j.jaut.2019.03.005_bib16) 2018; 91
Noguchi (10.1016/j.jaut.2019.03.005_bib21) 2017; 74
Watanabe (10.1016/j.jaut.2019.03.005_bib20) 2016; 87
Shiina (10.1016/j.jaut.2019.03.005_bib26) 2012; 80
Suzuki (10.1016/j.jaut.2019.03.005_bib38) 2009; 66
Vallet (10.1016/j.jaut.2019.03.005_bib13) 2016; 27
Haratani (10.1016/j.jaut.2019.03.005_bib35) 2018; 4
Brahmer (10.1016/j.jaut.2019.03.005_bib4) 2018; 36
Cuzzubbo (10.1016/j.jaut.2019.03.005_bib9) 2017; 73
Ishida (10.1016/j.jaut.2019.03.005_bib1) 1992; 11
Wick (10.1016/j.jaut.2019.03.005_bib8) 2016; 17
Takamatsu (10.1016/j.jaut.2019.03.005_bib32) 2018; 5
Spain (10.1016/j.jaut.2019.03.005_bib6) 2016; 44
Spain (10.1016/j.jaut.2019.03.005_bib11) 2017; 28
Makarious (10.1016/j.jaut.2019.03.005_bib40) 2017; 82
Weber (10.1016/j.jaut.2019.03.005_bib34) 2017; 35
Cao (10.1016/j.jaut.2019.03.005_bib28) 2001; 62
Oken (10.1016/j.jaut.2019.03.005_bib22) 1982; 5
Johnson (10.1016/j.jaut.2019.03.005_bib27) 2016; 375
Onda (10.1016/j.jaut.2019.03.005_bib19) 2019
Allenbach (10.1016/j.jaut.2019.03.005_bib30) 2016; 139
References_xml – volume: 43
  start-page: 62
  year: 2017
  end-page: 81
  ident: bib33
  article-title: Integrated classification of inflammatory myopathies
  publication-title: Neuropathol. Appl. Neurobiol.
– volume: 74
  start-page: 1216
  year: 2017
  end-page: 1222
  ident: bib10
  article-title: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies
  publication-title: JAMA Neurol
– volume: 138
  start-page: 743
  year: 2018
  end-page: 745
  ident: bib15
  article-title: Immune checkpoint inhibitor-associated myositis
  publication-title: Circulation
– volume: 27
  start-page: 266
  year: 2017
  end-page: 268
  ident: bib39
  article-title: Myasthenia triggered by immune checkpoint inhibitors: new case and literature review
  publication-title: Neuromuscul. Disord.
– volume: 1
  start-page: 57
  year: 1966
  end-page: 60
  ident: bib25
  article-title: Myasthenia gravis. Immunological relationship between striated muscle and thymus
  publication-title: Lancet
– volume: 5
  start-page: 1421
  year: 2018
  end-page: 1427
  ident: bib32
  article-title: Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
  publication-title: Ann Clin Transl Neurol
– volume: 87
  start-page: 1038
  year: 2016
  end-page: 1044
  ident: bib20
  article-title: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 5
  start-page: 649
  year: 1982
  end-page: 655
  ident: bib22
  article-title: Toxicity and response criteria of the eastern cooperative Oncology group
  publication-title: Am. J. Clin. Oncol.
– volume: 66
  start-page: 1334
  year: 2009
  end-page: 1338
  ident: bib38
  article-title: Autoimmune targets of heart and skeletal muscles in myasthenia gravis
  publication-title: Arch. Neurol.
– volume: 87
  start-page: 1954
  year: 2016
  end-page: 1955
  ident: bib36
  article-title: HLA-DRB1 alleles in immune-mediated necrotizing myopathy
  publication-title: Neurology
– volume: 375
  start-page: 1749
  year: 2016
  end-page: 1755
  ident: bib27
  article-title: Fulminant myocarditis with combination immune checkpoint blockade
  publication-title: N. Engl. J. Med.
– volume: 139
  start-page: 2131
  year: 2016
  end-page: 2135
  ident: bib30
  article-title: High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
  publication-title: Brain
– volume: 73
  start-page: 1
  year: 2017
  end-page: 8
  ident: bib9
  article-title: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature
  publication-title: Eur. J. Cancer
– volume: 11
  start-page: 3887
  year: 1992
  end-page: 3895
  ident: bib1
  article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
  publication-title: EMBO J.
– volume: 4
  start-page: 374
  year: 2018
  end-page: 378
  ident: bib35
  article-title: Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer
  publication-title: JAMA Oncol
– volume: 230
  start-page: 148
  year: 2011
  end-page: 152
  ident: bib37
  article-title: Clinical and immunological differences between early and late-onset myasthenia gravis in Japan
  publication-title: J. Neuroimmunol.
– volume: 91
  start-page: e985
  year: 2018
  end-page: e994
  ident: bib16
  article-title: Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
  publication-title: Neurology
– volume: 274
  start-page: 202
  year: 2014
  end-page: 208
  ident: bib24
  article-title: Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies
  publication-title: J. Neuroimmunol.
– volume: 62
  start-page: 1009
  year: 2001
  end-page: 1030
  ident: bib28
  article-title: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations
  publication-title: Hum. Immunol.
– year: 2019
  ident: bib19
  article-title: Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy
  publication-title: Intern. Med.
– volume: 348
  start-page: 56
  year: 2015
  end-page: 61
  ident: bib2
  article-title: The future of immune checkpoint therapy
  publication-title: Science
– volume: 89
  start-page: 1127
  year: 2017
  end-page: 1134
  ident: bib17
  article-title: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
  publication-title: Neurology
– volume: 80
  start-page: 305
  year: 2012
  end-page: 316
  ident: bib26
  article-title: Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers
  publication-title: Tissue Antigens
– volume: 17
  start-page: e529
  year: 2016
  end-page: e541
  ident: bib8
  article-title: Neurological sequelae of cancer immunotherapies and targeted therapies
  publication-title: Lancet Oncol.
– volume: 45
  start-page: 228
  year: 2009
  end-page: 247
  ident: bib23
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur. J. Cancer
– volume: 28
  start-page: iv119
  year: 2017
  end-page: i142
  ident: bib3
  article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann. Oncol.
– volume: 28
  start-page: 377
  year: 2017
  end-page: 385
  ident: bib11
  article-title: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
  publication-title: Ann. Oncol.
– volume: 36
  start-page: 1714
  year: 2018
  end-page: 1768
  ident: bib4
  article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical Oncology clinical practice guideline
  publication-title: J. Clin. Oncol.
– volume: 74
  start-page: 992
  year: 2017
  end-page: 999
  ident: bib21
  article-title: Skeletal muscle involvement in antisynthetase syndrome
  publication-title: JAMA Neurol
– volume: 82
  start-page: 128
  year: 2017
  end-page: 136
  ident: bib40
  article-title: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors
  publication-title: Eur. J. Cancer
– volume: 29
  start-page: 806
  year: 2016
  end-page: 812
  ident: bib7
  article-title: Neurologic complications of immune checkpoint inhibitors
  publication-title: Curr. Opin. Neurol.
– volume: 13
  start-page: 755
  year: 2017
  end-page: 763
  ident: bib12
  article-title: Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
  publication-title: Nat. Rev. Neurol.
– volume: 6
  year: 2018
  ident: bib18
  article-title: Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer
  publication-title: Respirology case reports
– volume: 35
  start-page: 785
  year: 2017
  end-page: 792
  ident: bib34
  article-title: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma
  publication-title: J. Clin. Oncol.
– volume: 378
  start-page: 158
  year: 2018
  end-page: 168
  ident: bib5
  article-title: Immune-related adverse events associated with immune checkpoint blockade
  publication-title: N. Engl. J. Med.
– volume: 27
  start-page: 1352
  year: 2016
  end-page: 1353
  ident: bib13
  article-title: Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
  publication-title: Ann. Oncol.
– volume: 44
  start-page: 51
  year: 2016
  end-page: 60
  ident: bib6
  article-title: Management of toxicities of immune checkpoint inhibitors
  publication-title: Cancer Treat Rev.
– volume: 16
  start-page: 693
  year: 2017
  end-page: 700
  ident: bib29
  article-title: Integrated diagnosis Project for inflammatory myopathies: an association between autoantibodies and muscle pathology
  publication-title: Autoimmun. Rev.
– volume: 4
  start-page: 36
  year: 2016
  ident: bib31
  article-title: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
  publication-title: J Immunother Cancer
– volume: 28
  start-page: 673
  year: 2017
  end-page: 675
  ident: bib14
  article-title: Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
  publication-title: Ann. Oncol.
– volume: 73
  start-page: 1
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib9
  article-title: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2016.12.001
– volume: 87
  start-page: 1954
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib36
  article-title: HLA-DRB1 alleles in immune-mediated necrotizing myopathy
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000003160
– volume: 11
  start-page: 3887
  year: 1992
  ident: 10.1016/j.jaut.2019.03.005_bib1
  article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
  publication-title: EMBO J.
  doi: 10.1002/j.1460-2075.1992.tb05481.x
– volume: 139
  start-page: 2131
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib30
  article-title: High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
  publication-title: Brain
  doi: 10.1093/brain/aww054
– volume: 27
  start-page: 266
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib39
  article-title: Myasthenia triggered by immune checkpoint inhibitors: new case and literature review
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2017.01.002
– volume: 27
  start-page: 1352
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib13
  article-title: Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw126
– volume: 5
  start-page: 649
  year: 1982
  ident: 10.1016/j.jaut.2019.03.005_bib22
  article-title: Toxicity and response criteria of the eastern cooperative Oncology group
  publication-title: Am. J. Clin. Oncol.
  doi: 10.1097/00000421-198212000-00014
– volume: 44
  start-page: 51
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib6
  article-title: Management of toxicities of immune checkpoint inhibitors
  publication-title: Cancer Treat Rev.
  doi: 10.1016/j.ctrv.2016.02.001
– volume: 5
  start-page: 1421
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib32
  article-title: Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.654
– volume: 6
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib18
  article-title: Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer
  publication-title: Respirology case reports
  doi: 10.1002/rcr2.355
– volume: 74
  start-page: 992
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib21
  article-title: Skeletal muscle involvement in antisynthetase syndrome
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2017.0934
– volume: 35
  start-page: 785
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib34
  article-title: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.66.1389
– volume: 28
  start-page: 673
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib14
  article-title: Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw655
– volume: 28
  start-page: iv119
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib3
  article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx225
– volume: 16
  start-page: 693
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib29
  article-title: Integrated diagnosis Project for inflammatory myopathies: an association between autoantibodies and muscle pathology
  publication-title: Autoimmun. Rev.
  doi: 10.1016/j.autrev.2017.05.003
– volume: 17
  start-page: e529
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib8
  article-title: Neurological sequelae of cancer immunotherapies and targeted therapies
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30571-X
– volume: 66
  start-page: 1334
  year: 2009
  ident: 10.1016/j.jaut.2019.03.005_bib38
  article-title: Autoimmune targets of heart and skeletal muscles in myasthenia gravis
  publication-title: Arch. Neurol.
  doi: 10.1001/archneurol.2009.229
– volume: 45
  start-page: 228
  year: 2009
  ident: 10.1016/j.jaut.2019.03.005_bib23
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.10.026
– volume: 13
  start-page: 755
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib12
  article-title: Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
  publication-title: Nat. Rev. Neurol.
  doi: 10.1038/nrneurol.2017.144
– volume: 138
  start-page: 743
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib15
  article-title: Immune checkpoint inhibitor-associated myositis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.118.035898
– volume: 43
  start-page: 62
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib33
  article-title: Integrated classification of inflammatory myopathies
  publication-title: Neuropathol. Appl. Neurobiol.
  doi: 10.1111/nan.12380
– volume: 348
  start-page: 56
  year: 2015
  ident: 10.1016/j.jaut.2019.03.005_bib2
  article-title: The future of immune checkpoint therapy
  publication-title: Science
  doi: 10.1126/science.aaa8172
– volume: 74
  start-page: 1216
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib10
  article-title: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2017.1912
– volume: 62
  start-page: 1009
  year: 2001
  ident: 10.1016/j.jaut.2019.03.005_bib28
  article-title: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations
  publication-title: Hum. Immunol.
  doi: 10.1016/S0198-8859(01)00298-1
– volume: 82
  start-page: 128
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib40
  article-title: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2017.05.041
– volume: 89
  start-page: 1127
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib17
  article-title: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000004359
– volume: 1
  start-page: 57
  year: 1966
  ident: 10.1016/j.jaut.2019.03.005_bib25
  article-title: Myasthenia gravis. Immunological relationship between striated muscle and thymus
  publication-title: Lancet
  doi: 10.1016/S0140-6736(66)92356-7
– volume: 80
  start-page: 305
  year: 2012
  ident: 10.1016/j.jaut.2019.03.005_bib26
  article-title: Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers
  publication-title: Tissue Antigens
  doi: 10.1111/j.1399-0039.2012.01941.x
– volume: 230
  start-page: 148
  year: 2011
  ident: 10.1016/j.jaut.2019.03.005_bib37
  article-title: Clinical and immunological differences between early and late-onset myasthenia gravis in Japan
  publication-title: J. Neuroimmunol.
  doi: 10.1016/j.jneuroim.2010.10.023
– year: 2019
  ident: 10.1016/j.jaut.2019.03.005_bib19
  article-title: Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy
  publication-title: Intern. Med.
  doi: 10.2169/internalmedicine.1956-18
– volume: 4
  start-page: 36
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib31
  article-title: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-016-0139-8
– volume: 375
  start-page: 1749
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib27
  article-title: Fulminant myocarditis with combination immune checkpoint blockade
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1609214
– volume: 28
  start-page: 377
  year: 2017
  ident: 10.1016/j.jaut.2019.03.005_bib11
  article-title: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw558
– volume: 87
  start-page: 1038
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib20
  article-title: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp-2016-313166
– volume: 29
  start-page: 806
  year: 2016
  ident: 10.1016/j.jaut.2019.03.005_bib7
  article-title: Neurologic complications of immune checkpoint inhibitors
  publication-title: Curr. Opin. Neurol.
  doi: 10.1097/WCO.0000000000000391
– volume: 91
  start-page: e985
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib16
  article-title: Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000006124
– volume: 36
  start-page: 1714
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib4
  article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical Oncology clinical practice guideline
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.77.6385
– volume: 4
  start-page: 374
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib35
  article-title: Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.2925
– volume: 274
  start-page: 202
  year: 2014
  ident: 10.1016/j.jaut.2019.03.005_bib24
  article-title: Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies
  publication-title: J. Neuroimmunol.
  doi: 10.1016/j.jneuroim.2014.07.006
– volume: 378
  start-page: 158
  year: 2018
  ident: 10.1016/j.jaut.2019.03.005_bib5
  article-title: Immune-related adverse events associated with immune checkpoint blockade
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1703481
SSID ssj0011555
Score 2.5209253
Snippet To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1...
To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).OBJECTIVETo characterize the inflammatory myopathy...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 105
SubjectTerms Autoantibodies
Creatine kinase
Human leucocyte antigen
Inflammatory myopathy
Programmed cell death 1
Title Inflammatory myopathy associated with PD-1 inhibitors
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0896841119300393
https://dx.doi.org/10.1016/j.jaut.2019.03.005
https://www.ncbi.nlm.nih.gov/pubmed/30862448
https://www.proquest.com/docview/2191009570
Volume 100
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8UwDA-iKF7Eb59fTPAm861r99Gj-MFTUQQVvJV2a3Gie6LPw7v4t5ts3QMPKnjcSFhJml-TJWkA9gsr0yyOZKhZpkPBHJpULOMw1s6WQmPcoql3-Oo6HdyLi4fkYQqOu14YKqv02N9ieoPW_k3fS7P_WlX92yiXaS7QViVvOkypg11ktMsPPydlHujwNJNPiTgkat8409Z4PVGVCB6B_qLT5KfD6SfnszmEzhZhwXuPwVG7wCWYsvUyzLbzJMfLMHflM-UrkJzXDpX90iTRg5fxkEYPjwPttWHLgP7ABjcnIQuq-rEyFY3dWYX7s9O740HoRySEBUZio1AkmUkjF1kpuMtTbUzscsNSy2Kjc7ROl0nLTC64QdKysLG0qRSlKHKDkKv5GkzXw9puQICBUclEoiV3keBIiIEhuiNRqU3hTFL0gHWyUYW_P5zGWDyrrlDsSZE8FclTRVyhPHtwMOF5bW_P-JWadyJXXV8oIplCcP-VK5lwfds5f_LtdVpVaFKUJ9G1HX68KwRxRq5nFvVgvVX3ZPWcQkAMaTf_-dUtmKentthsG6ZHbx92B92akdlt9u0uzBydXw6uvwBWt_SD
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LSsNAcNCKj4v4tj4jeJPQbHbz2GNRS6u2CCp4W3aTXYxoKloP_Xtnk03BgwpekxmyzOy8Mi-A00zzOAkD7kuSSJ8RgyIV8tAPpdE5kxi3SNs7PBzF_Qd29Rg9zsF50wtjyyqd7q91eqWt3ZOOo2bnrSg6d0HK45ShrHJadZjOw4KdThW1YKE7uO6PZskENJlVJSPC-xbB9c7UZV7PtlAEraCbdRr9ZJ9-8j8rO9Rbg1XnQHrd-ozrMKfLDVisV0pON2Bp6JLlmxANSoP8fq3y6N7rdGy3D0896Riic8_-hPVuL3ziFeVToQq7eWcLHnqX9-d9321J8DMMxiY-ixIVBybQnFGTxlKp0KSKxJqESqYooCbhmqiUUYWgeaZDrmPOcpalCrWupNvQKsel3gUPY6OcsEhyagJGERBjQ_RIglyqzKgoawNpaCMyN0LcbrJ4EU2t2LOw9BSWniKgAunZhrMZzls9QONXaNqQXDStoajMBOr3X7GiGda3y_Mn3knDVYFSZVMlstTjzw-BepxY7zMJ2rBTs3t2emqjQIxq9_751WNY7t8Pb8TNYHS9Dyv2TV17dgCtyfunPkQvZ6KO3C3-Ar3y9zQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammatory+myopathy+associated+with+PD-1+inhibitors&rft.jtitle=Journal+of+autoimmunity&rft.au=Seki%2C+Morinobu&rft.au=Uruha%2C+Akinori&rft.au=Ohnuki%2C+Yuko&rft.au=Kamada%2C+Sachiko&rft.date=2019-06-01&rft.eissn=1095-9157&rft.volume=100&rft.spage=105&rft_id=info:doi/10.1016%2Fj.jaut.2019.03.005&rft_id=info%3Apmid%2F30862448&rft.externalDocID=30862448
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0896-8411&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0896-8411&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0896-8411&client=summon